Vorsetuzumab mafodotin
Names
[ CAS No. ]:
1165741-01-4
[ Name ]:
Vorsetuzumab mafodotin
Biological Activity
[Description]:
Vorsetuzumab mafodotin (SGN-75) is an Auristatin-based anti-CD70 antibody-drug conjugate (ADC). Vorsetuzumab mafodotin consists of a humanized monoclonal antibody, Vorsetuzumab and an ADC cytotoxin MMAF. Vorsetuzumab mafodotin has antineoplastic activity[1].
[Related Catalog]:
[In Vitro]
Vorsetuzumab mafodotin (SGN-75; 0.01-10000 ng/mL; for 96 h) induces dose-dependent cytotoxicity that is specific with an IC50 of 29 ng/mL[1]. Cell Cytotoxicity Assay[1] Cell Line: SK-OV-3 cells Concentration: 0.01 ng/mL, 0.1 ng/mL, 1 ng/mL, 10 ng/mL, 100 ng/mL, 1000 ng/mL, 10000 ng/mL Incubation Time: 96 h Result: Induced dose-dependent cytotoxicity.
[In Vivo]
Vorsetuzumab mafodotin (SGN-75; 3 mg/kg; four intraperitoneal injections at 4-day interval) significantly reduces median tumour volumes and delays tumour growth[1]. Animal Model: Nude (nu/nu) female mice injected with MiaPaCa-2/CD70 tumour pieces[1] Dosage: 3 mg/kg Administration: Intraperitoneal injection; every 4 days; for a total of four doses Result: Significantly reduced median tumour volumes and delayed tumour growth.
[References]
Chemical & Physical Properties
[ Molecular Weight ]:
150 (kDa)
Related Compounds
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.